Business Wire

REPLY

23.4.2024 12:44:33 CEST | Business Wire | Press release

Share
REPLY S.p.A.: Shareholders’ Meeting Approves the 2023 Financial Statements

The General Shareholders’ meeting of Reply S.p.A. [EXM, STAR: REY] today approved the Financial Statements for the financial year 2023, confirming the distribution of a gross dividend of €1.00 per share.

The dividend will be paid on 22 May 2024, with dividend date set on 20 May 2024 (record date on 21 May 2024).

2023 Financial Statement

The Reply Group closed the 2023 financial year with a consolidated turnover of €2,118.0 million, recording a 12.0% increase compared to €1,891.1 million in 2022.

Consolidated EBITDA was €325.1 million, up 3.5% compared to €340.3 million recorded in 2022 (growth yoy is 20% net of the release of COVID funds accounted in 2022).

EBIT, from January to December, was €292.7 million, up 2.5% compared to €285.5 million recorded in 2022 (growth yoy is 22.7% net of the release of COVID funds accounted in 2022).

The Group net profit was at €186.7 million. In 2022, the corresponding figure was €191.0 million.

The Shareholders’ Meeting also adopted the following resolutions:

Appointment of the Board of Directors and the Board of Statutory Auditors for the three-year period 2024-2026

The Shareholders' Meeting has appointed the new members of the Board of Directors and the Board of Statutory Auditors for the three-year period 2024-2026, based on the lists of candidates submitted by the shareholders.

The following have been appointed as Directors:

- Mario Rizzante (Chairman), Tatiana Rizzante, Filippo Rizzante, Marco Cusinato, Elena Maria Previtera, Daniele Angelucci, Domenico Giovanni Siniscalco (who declared that he meets the independence requirements provided for in Article 148 of the TUF and the Corporate Governance Code) and Patrizia Polliotto (who declared that she meets the independence requirements provided for in Article 148 of the TUF and the Corporate Governance Code), taken from the majority list submitted by the shareholder Alika S. r.l. (holder of a shareholding equal to 39.754% of Reply S.p.A.'s share capital), which obtained the highest number of votes (63.957% of votes obtained);

- Secondina Giulia Ravera and Federico Ferro-Luzzi, both of whom declared to possess the independence requirements foreseen by article 148 of the TUF and by the Corporate Governance Code, taken from the minority list presented by a group of Investors (holding a total shareholding equal to 3.968% of Reply S.p.A.'s share capital).

The new Board of Statutory Auditors appointed is composed of three Standing Auditors and two Alternate Auditors:

- Ciro Di Carluccio (Chairman) and Gabriella Chersicla (Alternate Auditor), who declared that they meet the independence requirements provided for by article 148 of the TUF and the Corporate Governance Code, taken from the minority list presented by a group of Investors (holding a total of 4.978% of Reply S.p.A.'s share capital);

- Piergiorgio Re (Standing Auditor), Donatella Busso (Standing Auditor), Stefano Barletta (Alternate Auditor), who declared they meet the independence requirements provided for by article 148 of TUF and the Corporate Governance Code, drawn from the majority list submitted by the shareholder Alika S.r.l. (owner of a 39.754% shareholding in Reply S.p.A.), which obtained the highest number of votes (63.821% of votes obtained).

The curricula vitae of the Directors and Statutory Auditors, as well as the additional documentation required by current regulations, are available in the investors section of the website www.reply.com

Approval of the Program for the Acquisition and/or Disposal of Treasury Shares

The Shareholders’ Meeting authorised a new share buyback program, while withdrawing the current one approved at the Shareholders’ Meeting of 20 April 2023: the main objective of this program is the purchase of shares to implement the stock incentive plans, transactions aimed at the acquisition of equity investments, extraordinary financial transactions and/or the conclusion of agreements with strategic partners.

The authorization has a duration of 18 months from the date of the resolution, for a maximum of 3,607,950 ordinary shares (equal to 9.64398% of the current share capital) with a nominal value of €0.13 each for a maximum nominal value of €469,033.5, within the limit of a maximum financial commitment of €450,000,000. The purchase price may not be lower than the nominal value (currently €0.13) and higher than the official trading price recorded on the MTA market on the day before the purchase, increased by 20%.

Approval of the Remuneration Report

The Shareholders' Meeting also approved Sections I and II of the Remuneration Report drafted pursuant to Article 123-ter of Legislative Decree 58/1998.

The manager in charge of drafting the company's financial reports, Dr Giuseppe Veneziano, declares in accordance with Paragraph 2 of Article 154-bis of the Consolidated Finance Act, that the accounting information contained in this press release corresponds to the company's records, ledgers and accounting records.

This press release is a translation, the Italian version will prevail.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240423780149/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Investor Supporting Japan’s Entertainment Industry, Yoshihiro Shimamura, to Visit France Workshop to be Held During the Cannes Film Festival28.4.2026 04:00:00 CEST | Press release

Shimamura Yoshihiro Film Planning Inc. (Head Office: Osaka, Japan; CEO: Yoshihiro Shimamura), a company engaged in film production and investment, will host a workshop in France during this year’s Cannes Film Festival, as part of its commitment to further advancing the entertainment industry. The company invests in leading entertainment-related businesses in Japan and places strong emphasis on long-term value creation. It identifies the cultural and entertainment sectors as high-growth areas and is actively involved in international co-productions as a core part of its film production activities. As a recent investment, the company acquired 2,000,000 shares of Hankyu Hanshin Holdings, Inc.—a major Japanese entertainment conglomerate known for producing content enjoyed across generations—and became a major shareholder (as of March 25, 2026). Through such investments, the company aims to support the global expansion of Japanese entertainment while exploring synergies with its own interna

Alsym Energy Announces Na-Series Battery Success Developed With Physics-Informed AI Platform27.4.2026 21:25:00 CEST | Press release

Alsym’s proprietary physics-informed AI platform powered the development of its Na-Series batteries—a non-flammable, high performance and low cost energy solution positioned to serve critical energy storage markets including data centers, utilities, telecommunications, commercial real estate, industrial and defense, among others. Alsym Energy, a pioneer in non-flammable, high-performance sodium-ion batteries, today announced details of the proprietary physics-informed AI platform used to develop the company’s recently launched Na-Series sodium-ion batteries. By integrating fundamental physics models with AI, autonomous testing and proprietary molecular diagnostics in a closed-loop system, Alsym is accelerating the design of safer, inexpensive, commercialized batteries through all phases of the development cycle. As global demand for electricity surges, the limitations of lithium-ion batteries have become increasingly apparent, particularly around safety and supply chain constraints. Li

Backed by Investments Exceeding $1 Billion, PCI Pharma Services Announces Major Expansion of US Sterile Fill-Finish and Drug-Device Delivery Combination Capabilities27.4.2026 16:00:00 CEST | Press release

As pharma manufacturers prioritize US supply chain resilience, highlights include high-speed isolator filling lines for prefilled syringes, cartridges and vials, and drug-device combination assembly and packaging. PCI Pharma Services (“PCI”) – a world-leading integrated global contract development and manufacturing organization (CDMO) focused on innovative biologic and small molecule therapies – announced a series of major infrastructure investments that substantially deepen its sterile fill-finish and advanced drug delivery capabilities. As pharma manufacturers and their development partners increasingly prioritize US supply chain resilience, PCI’s latest investments come as part of a broader commitment exceeding $1 billion across the CDMO’s US and European operations, reinforcing its ability to provide seamless support for drug product development and manufacturing, clinical trial supply and drug-device combination assembly from clinical stages through commercial launch – all underpi

Pure Lithium Appoints Renowned Battery Expert Dr. Yuan Gao to Board of Directors27.4.2026 15:53:00 CEST | Press release

Pure Lithium Corporation, a vertically integrated lithium metal battery technology company, is pleased to announce that world-renowned inventor and battery expert Dr. Yuan Gao has joined the company’s Board of Directors. Dr. Gao has been an invaluable member of Pure Lithium’s Scientific Advisory Board since October of 2023. "We are thrilled to have Dr. Gao join our board as we focus on rapidly scaling our technology in the most capital efficient manner possible,” said Pure Lithium Founder, Chairman and CEO Emilie Bodoin. “Dr. Gao is a brilliant scientist who also has deep commercial expertise, a rare combination. He is also unique in the industry because his experience spans the entire battery materials value chain, including all of Pure Lithium’s verticals. His insights over the years have been critical in advancing our technology, and his experience as a director of public companies will strengthen our board.” Dr. Gao commented: “I am thrilled to join the board of Pure Lithium Corpor

Taiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical Development27.4.2026 15:00:00 CEST | Press release

Phase 1 dose-escalation trial represents the first clinical trial of a product developed using the AraLinQ™ ADC technology and marks Taiho’s expansion into the clinical development of ADCs for oncology Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG (“Araris”) today announced that the U.S. Food and Drug Administration (FDA) has completed its Investigational New Drug (IND) review period for ARC-02, an antibody-drug conjugate (ADC) being developed for the treatment of non-Hodgkin lymphoma, enabling Taiho Oncology to initiate a Phase 1 dose-escalation clinical trial of ARC-02. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427127507/en/ Taiho Pharmaceutical acquired Araris Biotech in March 2025, expanding Taiho group’s capabilities in biologics and ADC research and development. Araris is a spin-off of the Paul Scherrer Institute and ETH in Switzerland focused on the development of antibody-drug co

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye